Champions Oncology, Inc. (CSBR)

Champions Oncology, Inc.'s stock price has been impacted by several earnings reports and broader market trends, with a decline of 10.97% between December 23, 2024, and December 19, 2025. The company reported an EPS of -$0.13 for Q4 2025. For Q1 2026, the company reported an EPS of $0.02, with revenue at $14.0 million, and the stock gained 21.52%. For Q2 2026, the company posted an EPS of $0.06, with total revenue increasing by 11% year-over-year to $15 million, and the stock surged 16.07% in after-hours trading.

Champions Oncology primarily manages and evaluates its performance on an annual basis, suggesting that explicit, strong seasonal patterns in demand for its oncology research services and products are not a primary focus. The company notes that radiopharmaceutical expansion and AI data platforms are expected to drive long-term oncology research demand.

Champions Oncology, Inc. is a technology-enabled research company focused on providing solutions for drug discovery and development in oncology. The company offers technology solutions for drug discovery and development, as well as personalized cancer care. Its core offerings include the TumorGraft technology platform, Translational Oncology Solutions, and Lumin Bioinformatics. The company markets its products through the internet and a dedicated sales force to pharmaceutical and biotechnology companies.

Headquartered in Hackensack, New Jersey, Champions Oncology, Inc. is a USA-based company that supports studies globally, with clinical sites, laboratories, and a scientific team strategically distributed around the world.

Champions Oncology aims to establish a global leadership position in oncology research and cultivate a solid reputation for the quality of its data acquisition and interpretation. The company has been actively investing in its data platform to enhance functionality and support pharmaceutical partners, which contributes positively to its reputation within the industry. Recent financial reports highlighting strong revenue growth and improved gross margins also reflect positively on the company's operational effectiveness and market position.

The ownership structure of Champions Oncology, Inc. includes institutional investors owning approximately 32.17% to 41.87% of the shares, with major holders including Battery Management Corp., NEA Management Company, LLC, Vanguard Group Inc, Tocqueville Asset Management L.p., and BlackRock, Inc. Insiders hold a substantial portion, ranging up to 46.98%, with Michael Maurice Brown being the largest individual shareholder. Retail investors hold around 47.13% of the shares.